We are live on ! Find out more
QTTB icon

Q32 Bio

57 hedge funds and large institutions have $11.4M invested in Q32 Bio in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% more ownership

Funds ownership: 1.71%1.8% (+0.09%)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

2% less funds holding

Funds holding: 5857 (-1)

45% less capital invested

Capital invested by funds: $20.8M → $11.4M (-$9.38M)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
57
Holders Change
-1
Holders Change %
-1.72%
% of All Funds
0.83%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
6
Reduced
11
Closed
10
Calls
$21K
Puts
Net Calls
+$21K
Net Calls Change
-$54K

QTTB Hedge Fund Activity: Q4 2023 in Review

57 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q4 2023, worth a combined $11.4M — down 45% from $20.8M a quarter earlier.

Fund positioning in QTTB was balanced in Q4 2023: 10 funds opened new positions, 10 closed out, 6 added to existing stakes and 11 trimmed.

The largest buyer was Newtyn Management, opening a new position worth an estimated $1.14M. The largest seller was Citadel Advisors, cutting an estimated $658K.

  • 57 institutional investors held Q32 Bio (QTTB) as of Q4 2023, down from 58 in Q3 2023.
  • Funds reported $11.4M of Q32 Bio stock for Q4 2023, down 45% quarter-over-quarter.
  • 10 funds opened new Q32 Bio positions in Q4 2023 and 10 closed out, a net change of 0 holders.
  • The largest Q32 Bio buyer in Q4 2023 was Newtyn Management, an estimated $1.14M added.
  • The largest Q32 Bio seller in Q4 2023 was Citadel Advisors, an estimated $658K sold.

Based on aggregated 13F filings for Q4 2023.